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The present study was conducted as an evaluation of a two-year pilot program started
in 1998 in the Netherlands to provide free hepatitis B vaccination targeted at drug users
(DUs). In order to identify which demographic and social-cognitive factors predict
vaccination uptake, written questionnaires were distributed in three pilot regions (Am-
sterdam, Tiel, and Maastricht) amongst all DUs that were invited to participate in the
program during a 2-month period. Vaccination behavior 2 years later was anonymously
and prospectively linked to the questionnaire data, which allowed us to investigate which
factors predict vaccination behavior. Of the 207 DUs eligible for vaccination (i.e., who
were not immune and/or had no current infection with the virus), 93 DUs had obtained
vaccination in the 2 years following the questionnaire. More than half of them (N =
50) had completed the full program (3 injections). As possible predictors of vaccination
uptake, the questionnaire included constructs of the Theory of Planned Behavior as well
as of the Health Belief Model. Our results show that attitude toward obtaining hepati-
tis B vaccination was positively associated with intention toward obtaining hepatitis B
vaccination. However, perceived behavioral control was found to be the only construct
related to actual vaccination uptake. None of the demographic variables were related to
vaccination uptake. Our findings suggest that future interventions aimed at increasing
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2146 Baars et al.
uptake of vaccination against hepatitis B in DUs should address DUs (perceived) control
concerning this behavior. The study’s limitations are noted.
Keywords Drug users; vaccination; hepatitis B, social-cognitive determinants; health
behavior; prevention
Introduction
Hepatitis B is an infectious disease of the liver caused by the hepatitis B virus. It is directly
transmitted through unsafe sex and blood contact. The hepatitis B virus is 50 to 100 times
more contagious than HIV (WHO, 2000). Approximately 90% of adult infections resolve
completely, leaving life-long immunity; 10% remain chronically infected. These latter pa-
tients have an increased risk for developing liver cirrhosis and liver cancer (WHO, 2000). A
safe and effective vaccine against hepatitis B is available since 1982 (CDC, 1982) and con-
sists of three injections. Hepatitis B is a serious global health problem with 2 billion people
who have been infected, and more than 350 million chronically infected (WHO, 2000).
Drug users (DUs) are at risk for hepatitis B through unsafe injecting drug use as well
as through unsafe sexual behavior. In Europe, 20 to 60% of DUs show markers of previous
infection (EMCDDA, 2003). Sharing needles, but also sharing injection equipment like
cottons, rinse water, cookers, mixers, as well as the sharing of drug solutions between two
syringes (front-loading and back-loading) may carry a risk of transmitting blood-borne
viruses like the hepatitis B (Koester, Booth, and Zhang, 1996). In the Netherlands, the
percentage of injecting DUs who share needles seems to be declining. For example in
Rotterdam, a city with many facilities for needle exchange programs, the percentage of
injecting DUs that recently shared needles decreased from 18% in 1994 to 8% in 2002 (De
Boer et al., 2004). Risky sexual behavior among DUs, however, remains prevalent through
inconsistent condom use with casual and primary sexual partners (EMCDDA, 2001; Booth,
Kwiatkowski, and Chitwood, 2000).
After the Health Counsil of the Netherlands advised the Dutch Ministry of Health to
vaccinate risk groups for hepatitis B, in 1998, a targeted vaccination approach was directed
at men who have sex with men, heterosexuals with multiple sex partners (i.e., sex workers),
and DUs (Van Steenbergen, 2002). The goal of this 2-year pilot program was to evaluate
strategies to enhance recruitment for hepatitis B vaccination and improve compliance (Van
Steenbergen, 2002). It was coördinated by the Dutch Centre for Infectious Disease Control
and financed by the Dutch Ministry of Health. The present study evaluates this pilot program.
After the pilot program ended, the vaccination campaign was continued by the Netherlands
association for community health services in 2002, and developed into a national campaign.
The results of our study were taken into account in the development of their policy toward
the vaccination of DUs against hepatitis B.
During the pilot program the hepatitis B vaccination was offered free of charge accord-
ing to the 6-months schedule: at 0, 1, and 6 months. When receiving their first vaccination,
participants were serologically tested for markers of previous hepatitis B infection. Those
who were not positive for hepatitis B virus received their first dose and were urged to get their
second and third dose after the 1st and 6th month in order to comply with the vaccination
procedure. Seven municipal health services within the Netherlands were selected for free
distribution of hepatitis B vaccines to be implemented. In all participating municipal health
services’ areas hepatitis B vaccination was promoted through flyers that explained local
vaccination procedures in different languages in order to reach those who do not speak or
































































































Drug Users’ Participation in a Free Hepatitis B Vaccination Program 2147
regions: Amsterdam, Tiel, Heerlen, and Maastricht. For DUs, enhanced outreach meant that
vaccination was performed mainly at onsite locations, such as sites for methadone outlet,
needle exchange, and homeless shelters. Our study was directed at measuring the effect of
this outreaching approach.
Previous studies among DUs have reported completion rates of hepatitis B vaccination,
varying from low completion rates (20%–31%; Des Jarlais et al., 2001; Christensen et al.,
2004; Seal et al., 2003), to intermediate (41%–63%; Christensen et al., 2004; Lum et al.,
2003; Ompad et al., 2004; McGregor, Marks, Hayward, Bell, and Slack, 2003; Van Houdt
et al., 2006; Van Steenbergen, 2002), to high-compliance rates (66%–88%; Altice, Bruce,
Walton, and Buitrago, 2005; Budd, Robertson, and Elton, 2004; Christensen et al., 2004;
Des Jarlais et al., 2001; Lugoboni et al., 2004; Rogers and Lubman, 2005; Seal et al., 2003;
Quaglio et al., 2002) depending on the use of different vaccination schedules, onsite vacci-
nation possibilities, and the use of monetary incentives. However, only some of these studies
identified social-demographic factors (age, ethnic background, and homelessness), and risk
factors concerning drug use (i.e., injecting drug use) associated with vaccine completion
(Altice et al., 2005; Lum et al., 2003; Ompad et al., 2004, Seal et al., 2003). Our study is
the first to explain vaccination behavior of DUs in the light of constructs of the Theory of
Planned Behavior (TPB), (Ajzen, 1991) and the Health Belief Model (HBM), (Rosenstock,
1965; Rosenstock, 1974). These theories have provided a useful theoretical framework to
predict health behavior, such as self-breast examination, condom use, smoking cessation,
and dietary change (Conner and Sparks, 1996; Sheeran and Abraham, 1996). Theory of
Planned Behavior assumes that (health) behavior and health behavior change result from
cognitive processes. The attitude toward a target behavior, combined with subjective norms
regarding that behavior and perceived control with respect to conducting the behavior are
expected to predict (motivation of) actual behavior. A person’s attitude is defined as the
subjective judgment of the target behavior: is it good, bad, sensible, or pleasant to obtain a
hepatitis B vaccination? Subjective norms express the way the individual expects other im-
portant persons like family, friends, or partner to think about him performing the behavior.
Perceived control is the conviction of the individual that he is or is not able to control his
own behavior and that he can successfully perform this behavior.
The HBM is an eclectic model with perceived severity and perceived susceptibility of
the health consequences that may result from not performing the target behavior, in this
case obtaining vaccination, as key variables. According to the HBM a person who rates
hepatitis B as a serious disease and assumes that his own chance of getting infected with
this disease is high, is more likely to obtain hepatitis B vaccination, as compared to those
who rate it as a less serious disease and/or those who assume that their own risk of getting
infected with hepatitis B is low.
The results of our study can contribute to improve future campaigns directed at promot-
ing vaccination (against hepatitis B) among DUs. Insight will be presented in the predictive
value of social-demographic, risk-behavioral (sexual and drug-related), and social-cognitive
determinants regarding hepatitis B vaccination behavior.
The main questions addressed in the present study are as follows:
1. Which percentage of the DUs that took part in this study had the intention to obtain
hepatitis B vaccination, which part actually obtained vaccination, and which part shows
vaccination completion?
2. Which (demographic, risk-behavioral, and social cognitive) determinants explain in-

































































































2148 Baars et al.
Methods
Procedure
The present study was conducted as an evaluation of the hepatitis B vaccination pilot
program. It took place in the regions in which the enhanced outreaching approach was used
to invite DUs to participate in the vaccination program. A total of 379 DUs were recruited:
282 in Amsterdam, 13 in Tiel, and 64 in Maastricht; of 20 DUs information about the
recruitment area is unavailable, because they did not fill in a zip code (those participants
were later excluded from further analysis, see section “participants”).
Our recruitment procedure was equal to that in the pilot program. Drug Users were
recruited by health professionals at drug-assistance agencies, at sites for methadone outlet
(in Amsterdam, Maastricht, and Tiel), needle-exchange sites (in Maastricht), and homeless
shelters (in Maastricht). Written questionnaires were distributed by health professionals
among DUs who visited these locations. After administration of the questionnaire, DUs
were informed about the possibility to obtain free vaccination against hepatitis B. This
procedure ensured us that respondents had not yet been informed about the possibility
of getting a free vaccination at the time of filling in the questionnaire, and had thus not
(yet) been influenced by information about the free hepatitis B campaign (through flyers or
outreach activities).
During the 2-year pilot program hepatitis B vaccination was administered free of
charge and available at all the locations described above. In methadone clinics screen-
ing and vaccination against hepatitis B was integrated in the usual routine, with vaccine
offered to all those who knew the Dutch or English language, could provide a zip code,
and planned at least 6 months residence in the area. If the DUs showed up for vaccina-
tion, they were registered with a unique personal identification code (which was also noted
on the questionnaire). This enabled us to prospectively link the determinants as measured
in this study to actual vaccination behavior. Informed consent for this procedure was ob-
tained. The implications of collecting data from individuals who are not likely to benefit
directly from their participation in our study were taken into account (Kleinig and Einstein,
2006).
Measurement
The written questionnaire that was used in our study contained several social-demographic
variables as well as variables related to risk behavior such as sexual behavior and drug intake,
variables that measured vaccination uptake and infection, and social-cognitive constructs
of the HBM and TPB.
Operationalisation of the Social-Demographic and Risk-Behavioral Factors. Table 1 shows
the measurement of the social-demographic and risk-behavioral factors.
Operationalisation of Hepatitis B Infection and Vaccination. Infection with the hepatitis
B virus was detected by self-report (Table 2). In addition, DUs who accepted the offer of
vaccination had a blood sample taken for hepatitis B. If DUs were (ever) infected with
the virus, the hepatitis B test showed markers of previous infection. The questions that are
shown in Table 2 and the results of the blood sample were used in our study to select those
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Table 1




Gender “What is your gender?” Male, female
Religion “What is your religion?” . . . . . . ..
Education “What is the highest educational
degree that you have
obtained?”
I have not finished any school
(also not primary school),
. . . , university
Ethnicity “What is your place of birth?” . . . . . . ..
Age “How old are you?” . . . years
Drug use behavior
Drug use “In general, how many times did
you use the following drugs:
heroin, cocaine, speedballs,
speed?”
Never; less than 1 time per
month; a few times per
month; a few times per
week; (almost) daily




Steady partner “Do you have a steady partner?” No, yes
No. of sex partners “How many different sex
partners did you have in the
past six months, do you
think?”
About . . . sex partners




Having paid for sex “Have you ever paid for sex?” Never, sometimes, regularly,
often, always
Operationalisation of the Social-Cognitive Constructs. Table 3 shows how the social-
cognitive factors were operationalised, the possible scores of the answers, and more in-
formation about their internal consistency.
Participants. Drug Users were defined as frequent users of illicit drugs (i.e., heroin, cocaine,
and/or amphetamines). Although the use of other substances, such as ecstasy, is also related
to unprotected sex (Choi et al., 2005), this study is limited to the goal population of the
pilot program.
Table 2
Operationalization of variables concerning hepatitis B infection and vaccination
Infection with hepatitis B “Did you ever get infected
with hepatitis B?”
No, yes


































































































2150 Baars et al.
Table 3
Operationalization of social-cognitive factors of hepatitis B vaccination behavior
Internal
Construct Question Answer consistency
Perceived
severity
“How serious would you find






“What is the probability of
you getting infected with
















“Do you think you are






“Are there any aspects of your
lifestyle that make it harder





Attitude “What do you think about
getting vaccinated against









Intention “If it is free of charge, are you
planning to get vaccinated
against hepatitis B within







“What is the probability that
you will get vaccinated
against hepatitis B in the
next 6 months, if it is free
of charge?”
1–7 (low, high)
A total of 379 DUs returned the questionnaire (response rate 55.5%). Forty-seven
respondents were omitted from the analyses because of insufficient data (19 had invalid
information on drug use, and 28 did not fill in an identification code in the question-
naire). Analyses (t-tests) and Chi-square tests comparing participants who did not provide
an identification code with those who did show that DUs who did not provide a code
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two-tailed) as compared to those who did provide the zip code, but that there was no
significant difference in the other variables that are shown in Table 1 between the two
groups.
Furthermore, 125 respondents were excluded as ineligible for vaccination on the fol-
lowing grounds: 29 reported previous vaccination, 76 reported previous infection, and 20
tested positive for hepatitis B markers. The remaining 207 respondents were included in
the analyses.
Statistical Analyses. Associations between demographic and behavioral variables (such as
drug use) and the dependent variables were analyzed using univariate statistics such as the
Chi-square test and t-test. The demographic and behavioral variables with a p-value below
.1 and all social-cognitive variables were included in multivariate regression analyses with
intention to obtain vaccination, vaccination uptake, and compliance with the full vaccination
schedule as the dependent variable. A p-value of .05 was considered significant.
Results
The majority of the 207 subjects in our sample were males (79.4%), with a mean age of
38.5 years (SD = 7.2). Participants had a low educational level, 31.8% having only finished
primary school or no education at all. The majority lived in Amsterdam (83.2%) and had
Dutch nationality (59.7%). Most DUs used heroin and/or cocaine. Daily heroin use was
reported by 47.9%; 37.6% used cocaine every day; and 19.2% injected drugs. More than
half of the DUs did not have a steady partner (64.5%). Of the female DUs, 25.0% had been
working as a prostitute and got paid for sex, compared to 3.6% of male DUs. Of men, 22.9%
had paid for sex themselves, but almost none on a regular basis (21.8% of DUs answered
“sometimes”). Of the 39 men who report to have paid for sex, 18 did not have any sex
partners in the preceding 4 months of entering the study. Modus of number of sex partners
(for both male and female DUs) in the preceding 6 months is 0, the median is 1, the mean
is 1.7, and the range is till 40. For further details, see Table 4.
On average, DUs who were eligible for vaccination had a high intention to obtain
hepatitis B vaccination at the start of the pilot program (DUs scored at a scale from 1 to 7 a
mean of 5.32, SD = 1.86, N = 207, see Table 5). By the end of the program in late 2000,
93 (44.9%) of 207 DUs had been vaccinated. More than half of them (N = 50) completed
the full program and received three injections; 14 DUs had received two injections (14%);
and 29 DUs had received only one injection (31%). More than half of the DUs (N = 114)
obtained no vaccination.
To understand DUs’ motivation for obtaining vaccination, mean scores and standard
deviations for factors of the TPB and HBM were calculated (Table 5). Mean scores show
that DUs think that their chances of becoming infected with the hepatitis B virus is low, but
that they would find it very serious if they got infected with the virus. Attitude, perceived
behavioral control, and intention toward vaccination are high.
Predicting Intention to Obtain Vaccination
Next we examined the association between social-demographic, behavioral, and social-
cognitive determinants of intention to obtain a hepatitis B vaccination (Table 6). Those
who identified with a religion had a higher intention to obtain vaccination. Attitude was
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Table 4
Selected background characteristics of participants (N = 207)


















> / = Sometimes 7.1
Speedballs






No. of sex partners
Mean 1.7 (4.0)
Being paid for sex
Yes 8.0
Having paid for sex
Yes 18.7
Table 5
Mean scores (SD) and range for social-cognitive factors of
vaccination behavior (N = 206)
Mean (SD) Range
Perceived severity 6.27 (1.45) 1–7
Perceived susceptibility 2.23 (1.76) 1–7
Perceived behavioral control 5.66 (1.37) 1–7
Attitude 6.31 (1.25) 1–7
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Table 6
Summary of linear regression analysis for variables predicting intention to obtain
hepatitis B vaccination (N = 206)1
B SE B β P-value
Step 1
Ethnicity −0.06 0.31 −0.02 0.85
Religion 0.93 0.31 0.24 0.003
Amphetamine use −0.85 0.54 −.12 0.12
Step 2
Ethnicity −0.32 0.28 −0.08 0.26
Religion 0.68 0.28 0.18 0.02
Amphetamine use −0.25 0.50 −0.03 0.61
Attitude 0.66 0.10 0.43 0.000
Perceived behavioral control 0.07 0.09 0.05 0.45
Step 3
Ethnicity −0.27 0.28 −0.07 0.34
Religion 0.65 0.28 0.17 0.02
Amphetamine use −0.19 0.49 −0.03 0.70
Attitude 0.60 0.10 0.39 0.000
Perceived behavioral control 0.09 0.09 0.07 0.31
Perceived susceptibility 0.13 0.07 0.12 0.07
Perceived severity 0.15 0.09 0.11 0.09
1Note: R2 = .08 for step 1, .27 for step 2 (p = .000), and .29 for step 3 (p = .07).
a positive attitude toward vaccination have a higher intention to obtain vaccination against
hepatitis B. Perceived severity and perceived susceptibility were marginally significant
predictors of intention to obtain vaccination.
Predicting Uptake of Vaccination (None versus 1, 2, 3 Vaccinations)
Univariate analyses show no significant differences between vaccinated and unvaccinated
DUs for the variables that are shown in Table 4.
Our results show that only perceived behavioral control was a significant predictor of
vaccination uptake in a logistic regression analyses with vaccination (1, 2, or 3) versus
no vaccination as a dependent variable. Attitude, intention, perceived susceptibility, and
perceived severity were not. In our model, 7% of the variance in vaccination uptake is
explained (Table 7).
Predicting Compliance with Full Vaccination (1, 2 versus 3 Vaccinations)
Drug Users who complied with the full vaccination schedule did not differ from those who
did not with regard to gender, age, having a steady partner, or number of sex partners.
Neither were behavioral determinants concerning drug use, i.e., the frequency of using
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Table 7
Summary of logistic regression analysis for variables predicting




Perceived behavioral control 1.34 1.07–1.67
Step 2
Attitude 0.92 0.70–1.20




Perceived behavioral control 1.34 1.06–1.67
Intention 1.08 0.91–1.29
Perceived susceptibility 0.91 0.79–1.08
Perceived severity 1.16 0.93–1.44
1Note: Nagelkerke R-square = .05 for step 1; Nagelkerke R-square =
.05 for step 2 (p = .40); Nagelkerke R-square = .07 for step 3 (p = .17).
Hosmer Lemeshow Chi-square = 9.95, p = .27.
Table 8
Summary of logistic regression analysis for variables predicting compliance
with the vaccination schedule (obtaining 3 hepatitis B vaccinations) (N = 92)1
OR 95% CI
Step 1
Injecting drug use 0.33 0.12–0.91
Step 2
Injecting drug use 0.31 0.11–0.88
Attitude 1.23 0.86–1.78
Perceived behavioral control 0.80 0.55–1.15
Step 3
Injecting drug use 0.30 0.11–0.86
Attitude 1.31 0.83–2.04
Perceived behavioral control 0.80 0.55–1.16
Intention 0.94 0.71–1.24
Step 4
Injecting drug use 0.34 0.12–0.98
Attitude 1.20 0.74–1.95
Perceived behavioral control 0.79 0.54–1.16
Intention 0.93 0.70–1.24
Perceived susceptibility 0.91 0.68–1.21
Perceived severity 1.37 0.91–2.06
1Note: Nagelkerke R-square = .07 for step 1; Nagelkerke R-square = .10 for step 2
(p = .27); Nagelkerke R-square = .11 for step 3 (p = .66); Nagelkerke R-square = .15
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who did not. However, injecting drug use was found to be univariately (Chi-square (1) =
4.55, p = .03) as well as multivariately related to vaccine completion. None of the following
social-cognitive factors such as attitude, intention, perceived susceptibility, and perceived
severity could predict compliance with the vaccination procedure (Table 8).
Discussion
Our prospective study shows that most DUs who participated in the survey had not yet been
vaccinated against hepatitis B and had not been infected with hepatitis B. The participants
in our study had a high intention to obtain vaccination at the start of the pilot program.
After 2 years, 93 of the 207 DUs who were eligible for vaccination had been vaccinated.
By receiving three injections, more than half of them completed the program.
Our results showed that DUs described themselves as being religious had a higher
intention to obtain vaccination within the next 6 months. In addition, those who had a
positive attitude toward obtaining vaccination had a higher intention to obtain vaccination
against hepatitis B. Perceived severity and perceived susceptibility to be infected with
hepatitis B were marginally related to intention to obtain hepatitis B vaccination. Perceived
behavioral control was the only social-cognitive construct that was related to vaccination
uptake, illustrating that DUs who found themselves more capable of receiving a vaccination
were more likely to obtain vaccination later in time. Injecting drug use was the only variable
significantly related to vaccine completion in the multivariate logistic regression analysis.
Among men who have sex with men more is known about social-cognitive factors that
influence vaccination behavior. De Wit, Vet, Schutten, and Van Steenbergen (2005) reported
that in this heterogeneous group perceived threat of hepatitis B infection was related to vacci-
nation behavior against hepatitis B. Rhodes, Grimley, and Hergenrather (2003) showed that
men with increased readiness to complete the 3-dose series of the hepatitis B vaccine per-
ceived lower practical barriers and greater benefits to vaccination, perceived higher severity
of infection, and had a higher self-efficacy to complete the vaccine series. Although our study
found that social-demographic variables, perceived severity, perceived susceptibility, and
attitude were not significantly related to vaccination behavior, the latter was associated with
intention. We did not find a relation between intention and behavior. Others have paid atten-
tion to the great discrepancy between behavioral intentions and actual behavior in social-
cognitive models (Orbell and Sheeran, 1998; Abraham et al., 1999; Sheeran and Abraham,
2003). The weak relationship between intention and behavior is largely due to people having
good intentions, but failing to act on them (Orbell and Sheeran, 1998; Gollwitzer, 1999).
This discrepancy has been labeled as the “intention-behavior gap.” Sheeran (2002) showed
in a meta-analysis that 47% of the participants with positive behavioral intentions failed to
perform the goal behavior. Contrary to the general population, most DUs live in an environ-
ment in which the primary necessities of life play a more important role than obtaining a
hepatitis B vaccination. Although DUs have a positive attitude and intention toward obtain-
ing vaccination, different barriers may play a role in their ability to obtain vaccination. Such
barriers may include finding a place to sleep, craving for drugs, or a period spent in jail; such
activities are urgent and time consuming, leaving little room for planning to obtain a hepatitis
B vaccination. The vaccination behavior of DUs should be explored further by investigat-
ing the benefits and barriers to obtain vaccination—two constructs of the HBM. Benefits
and barriers may also influence compliance, since none of the demographic and social-
cognitive factors as described in the present study were able to predict compliance with the
vaccination schedule. Des Jarlais et al. (2001) and Seal et al. (2003) showed that among

































































































2156 Baars et al.
Although Quaglio et al. (2002) showed among injecting DUs who participated in a
large cohort study, suboptimal vaccine responses when short-vaccine protocols are used
(0, 1, 2 months), different studies have indicated the use of accelerated vaccination sched-
ules (3-week or 2-month schedule) to be an acceptable alternative of the routine 6-month
schedule, because of a high and fast vaccine completion (Budd et al., 2004; Christensen et
al., 2004; Wright, Campbell, and Tompkins, 2002). It should however be kept in mind that
booster vaccinations are recommended after 12 months to ensure long-lasting immunity if
accelerated vaccination schedules are being used (Bock, 2003; Budd et al., 2004; Nothdurft
et al., 2002). The same barriers that influence vaccination completion rates at the 6-month
schedule could influence the uptake of the booster vaccination.
Completion rates were similar to those in earlier studies focusing on hepatitis B ad-
herence rates using the 6-month schedule among DUs, varying from 41% to 83% (Altice
et al., 2005; Des Jarlais et al., 2001; Lum et al., 2003; Ompad et al., 2004; Seal et al.,
2003; Van Houdt et al., 2006; Van Steenbergen, 2002), and in concordance with the fact
that within the Dutch pilot program nearly all vaccinations were received onsite, and no
monetary incentive was given. Lugoboni et al. (2004) showed that in Italy 88% of 320 DUs
had received three or more vaccinations; however, in that cohort study, participants were
studied over 15 years, and were followed up every 4 months. The extensive screening and
the longer period that free vaccination was available in that study may explain the higher
compliance among Italian DUs.
Study’s Limitations
Our study has several limitations that may influence the results. First, although the regis-
tration of the codes in order to be able to connect the questionnaire data to the vaccination
behavior was done with great care, it is possible that in some cases the registration system
failed. Consequently, the number of DUs that obtained vaccination may actually be greater
than the 93 (44.9%) that were reported here. A second limitation is that some of the respon-
dents did not provide an identification code. Those who did not provide the code were more
likely to be religious. It is not clear whether or how this selection bias influenced our results.
Third, compliance was not associated with any of the demographic, behavioral, and social-
cognitive determinants as measured in this study. This could be partly due to insufficient
power, since only 50 participants finished the full vaccination schedule. Fourth, since DUs
are a so-called hidden population (Watters and Biernacki, 1989) it is extremely difficult to
recruit a representative sample. Our study is a convenience sample, which is most likely
not fully representative of the total DU population. However, the sample does reflect the
population that was targeted in the pilot project, because the same recruitment procedures
were used for both the study and the pilot program. Additional study limitations include an
inadequate description of the sample and their adaptation skills and abilities. In our study
endogenous factors that influence vaccination behavior, i.e., social-cognitive factors, are
explored. Since exogenous factors, i.e., the frequency of visiting drug-assistance agencies
are not colleted as part of this study we can not draw conclusions about their interaction
with social-cognitive factors.
Conclusion
Our findings indicate that targeted free hepatitis B vaccination will increase the uptake of
vaccination against hepatitis B for DUs. Almost half of the 207 DUs who were eligible
for vaccination (i.e., who were not immune and/or had no current infection with the virus)
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completed the full vaccination schedule. Our study is the first in which social-cognitive de-
terminants were used to explain vaccination behavior against hepatitis B among DUs. Our
advice for future health interventions directed at increasing uptake of vaccination against
hepatitis B among DUs is to address perceived behavioral control, which we have demon-
strated to have a significant effect on vaccination uptake. Our research findings might be
useful for other vaccinations among DUs, for example vaccination against pneumococcus,
the influenza vaccine, or a possible future HIV vaccination.
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RÉSUMÉ
La présente étude a été menée pour évaluer un programme pilote de deux années qui a
commencé aux Pays-Bas en 1998, visant à vacciner gratuitement des toxicomanes contre
l’hépatite B. Pour cerner les déterminants démographiques et sociocognitifs de la vaccina-
tion, des questionnaires par écrit ont été distribués dans trois régions pilotes (Amsterdam,
Tiel et Maastricht) parmi tous les toxicomanes qui étaient invités à participer au programme
pendant deux mois. Au bout de deux ans, le comportement en matière de vaccination a été
comparé de manière anonyme et hypothétique aux résultats des questionnaires, ce qui nous
a permis d’étudier les facteurs influençant le comportement en matière de vaccination. Sur
les 207 toxicomanes éventuellement candidats à une vaccination (c’est-à-dire n’étant pas
immunisés et/ou n’ayant pas été contaminés par le virus), 93 toxicomanes s’étaient fait
vacciner dans les deux ans qui ont suivi le questionnaire. Plus de la moitié d’entre eux (N =
50) avait suivi le programme entier (3 injections). Le questionnaire comprenait des éléments
de la Theory of Planned Behavior (Théorie du comportement prévu), ainsi que du Health
Belief Model (Modèle des croyances liées à la santé)) comme déterminants éventuels de
la vaccination. Nos résultats montrent que l’attitude face à la vaccination contre l’hépatite
B est associée positivement à l’intention de se faire vacciner contre l’hépatite B. Toute-
fois, la perception du contrôle comportemental s’est avéré être le seul élément lié à une
vaccination effective. Aucun lien n’a pu être établi entre les facteurs démographiques et la
vaccination. Nos résultats suggèrent que les actions futures visant à augmenter le taux de
vaccination contre l’hépatite B parmi les toxicomanes doivent se concentrer sur le contrôle
comportemental perçu chez les toxicomanes. Les limites de cette étude sont prises en
considération.
Mots clés Toxicomanes, Vaccination, Hépatite B, éléments sociocognitifs; Comporte-
ment sanitaire, Prévention.
RESUMEN
El presente estudio se desarrolló como la evaluación de un programa piloto de dos años de
duración, que comenzó en 1998 en los Paı́ses Bajos con el objetivo de vacunar gratis a dro-
gadictos contra la hepatitis B. Para identificar los factores demográficos y socio-cognitivos
que preceden a la puesta de la vacuna se entregaron cuestionarios durante dos meses en
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participar en este programa. Dos años después el comportamiento con respecto a la vacuna se
relacionaba de manera anónima y hipotética con los datos del cuestionario, permitiéndonos
investigar los factores previos al comportamiento con respecto a la vacuna. De los 207 dro-
gadictos a los que se les administró la vacuna (es decir, que no eran inmunes y no estaban
infectados por el virus), 93 consiguieron vacunarse dos años después del cuestionario. Más
de la mitad de ellos (N = 50) finalizaron el programa completo (3 inyecciones). Como
posibles elementos vaticinadores de la puesta de la vacuna, el cuestionario incluı́a construc-
tos de la Theory of Planned Behavior (Teorı́a del comportamiento planificado), ası́ como
del Health Belief Model (Modelo de creencias de salud). Nuestros resultados demostraron
que la actitud frente a la obtención de la vacuna contra la hepatitis B estaba positivamente
asociada a la intención de obtener la vacuna contra la hepatitis B; sin embargo, la per-
cepción de comportamiento controlado se descubrió como el único constructo relacionado
con la puesta efectiva de la vacuna. Ninguna variable demográfica se relacionaba con ella.
Nuestros descubrimientos sugieren que las intervenciones futuras enfocadas a aumentar
la cobertura vacunal contra la hepatitis B en drogadictos deberı́an enfocarse al control
del comportamiento percibido de los drogadictos. Se apuntan, pues, las limitaciones del
estudio.
Palabras claves: drogadictos, vacuna, hepatitis B, determinantes socio-cognitivos,
comportamiento médico, prevención.
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Glossary
Compliance. Finishing the hepatitis B vaccination schedule by receiving three or more
vaccinations within 6 months.
Eligible for vaccination. In this study by eligible for vaccination we mean people who are
not immune to hepatitis B (those who have not been infected with the virus nor have
been fully vaccinated). They are qualifieds for hepatitis B vaccination.
Hepatitis B. It is a disease of the liver caused by the hepatitis B virus. The virus can cause
lifelong infection, cirrhosis of the liver, liver cancer, liver failure, and death.
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